Drug development and industrial pharmacy · 2026
Medium-chain fatty acid-enabled nanostructured lipid carriers for improved β-carotene biopharmaceutical properties and antioxidant efficacy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Wan-Yi, Fu Ting-Wen, Ko Horng-Huey, Chang Li-Ching, Wu Yu-Tse
Аннотация
OBJECTIVE: This study aimed to enhance the in vitro digestion and permeability of β-carotene (BC), a lipophilic antioxidant with therapeutic potential in oxidative stress-related disorders, by developing a nanostructured lipid carrier (NLC) system based on medium-chain fatty acids (MCFAs).
SIGNIFICANCE: Although BC exhibits strong antioxidant activity, its poor solubility and low gastrointestinal absorption limit clinical use. This study addresses these barriers by formulating a novel medium-chain fatty acid-based NLC using ethanol injection method that improves BC's solubility, permeability, and bioactivity. The approach offers a scalable oral promising platform for antioxidant therapies targeting chronic diseases linked to oxidative stress.
METHODS: BC-loaded NLC (BC-NLC) was prepared via ethanol injection and subsequently optimized using a Box-Behnken design. Physicochemical properties, biopharmaceutical performance, and antioxidant effects were evaluated.
RESULTS: The optimized BC-NLC showed a particle size of 153.9 nm, polydispersity index of 0.29, zeta potential of -14.1 mV, and encapsulation efficiency of 62.0%. In vitro digestion revealed 63-fold and 38-fold increases in BC micellar efficiency in simulated gastric and intestinal fluids, respectively. A 9.1-fold enhancement in intestinal transport was observed. Stability testing confirmed >88% BC retention over 28 days at 5 °C. Antioxidant assays demonstrated ≥2.3-fold higher radical scavenging activity and a 22.7-fold increase in reducing power compared to free BC.
CONCLUSIONS: The MCFAs-based BC-NLC effectively overcomes key biopharmaceutical limitations, offering enhanced in vitro digestion, stability, and antioxidant efficacy. It represents a promising oral delivery strategy for oxidative stress-related therapeutic applications.
SIGNIFICANCE: Although BC exhibits strong antioxidant activity, its poor solubility and low gastrointestinal absorption limit clinical use. This study addresses these barriers by formulating a novel medium-chain fatty acid-based NLC using ethanol injection method that improves BC's solubility, permeability, and bioactivity. The approach offers a scalable oral promising platform for antioxidant therapies targeting chronic diseases linked to oxidative stress.
METHODS: BC-loaded NLC (BC-NLC) was prepared via ethanol injection and subsequently optimized using a Box-Behnken design. Physicochemical properties, biopharmaceutical performance, and antioxidant effects were evaluated.
RESULTS: The optimized BC-NLC showed a particle size of 153.9 nm, polydispersity index of 0.29, zeta potential of -14.1 mV, and encapsulation efficiency of 62.0%. In vitro digestion revealed 63-fold and 38-fold increases in BC micellar efficiency in simulated gastric and intestinal fluids, respectively. A 9.1-fold enhancement in intestinal transport was observed. Stability testing confirmed >88% BC retention over 28 days at 5 °C. Antioxidant assays demonstrated ≥2.3-fold higher radical scavenging activity and a 22.7-fold increase in reducing power compared to free BC.
CONCLUSIONS: The MCFAs-based BC-NLC effectively overcomes key biopharmaceutical limitations, offering enhanced in vitro digestion, stability, and antioxidant efficacy. It represents a promising oral delivery strategy for oxidative stress-related therapeutic applications.